The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'July 2020'. If you still can't find what you are looking for, try using the search box.
Physiomics awarded contract by Astellas Pharma Inc.
Oxford, UK: Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that, further to its announcements of 27 May, 30 June and 22 July 2020, it has been awarded a contract by a new client, Astellas Pharma Inc. (TSE: 4503) (“Astellas”), a Japanese global pharmaceutical company.
The contract is for a modelling project involving Physiomics’ Virtual Tumour™ immuno-oncology model and relates to an undisclosed Astellas asset. The work is expected to be completed this calendar year. The precise value of the contract cannot be disclosed for reasons of commercial confidentiality however it is around 20% of the Company’s last full year’s total income to the 30 June 2019.
Dr Jim Millen, CEO said: “We are delighted to have ...
Read the rest of entry »
Oxford, UK: AMSBIO has introduced StemFit® for Differentiation - a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.
The unique chemically defined composition of StemFit® for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit® for Differentiation can be used to eliminate the risk of immunogenic contamination.
Applications proven to benefit from StemFit® for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.
Used in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit® for Differentiation enables res ...
Oxford, UK: AMSBIO offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.
Exosomes are small endosome derived lipid nanoparticles, actively secreted by exocytosis in most living cells. Acting on tissues in both the local environment and further afield, they function as important signal carriers through their transport of RNA, proteins, lipids and DNA. Exosomes are involved in a wide range of normal and pathogenic processes, making exosome research crucial in multiple areas. Exosomes are a type of extracellular vesicle (EV) that show promise for use as unique drug carriers to deliver protease inhibitors to treat COVID-19. In this application, EVs may provide targeted delivery of protease inhibitors, with fewer systemic side effects. More importantly, EVs are highly suitable for major aseptic processing and can be upscaled for mass production. Currently, the FDA is backing applications to treat COVID-19, which provides a very good ...
Cambrdige, UK: Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that encouraging results have been published for its small molecule dual tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitors in disease model studies of systemic lupus erythematosus (SLE) by its collaborator, SRI International.
These studies were supported by a research grant from the US Department of Defense (DoD) and the report was recently published on the website of the Defense Technical Information Center (https://apps.dtic.mil/sti/citations/AD1087498).
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influe ...
Norwich, UK: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression of proteins, vaccines, enzymes and complex natural products, is pleased to announce the recent appointment of Dr. Leanne Williams as Business Development Manager. Leanne has over 10 years’ experience working in the life sciences industry in both commercial and academic settings and will lead the growth of Leaf’s pipeline by identifying and establishing commercial collaborations within the global life science industry.
Northumberland, UK: Internationally renowned Industry veteran Steve Bagshaw joins Arcinova board to propel continued industry-leading growth
Arcinova, one of the fastest growing multi-service Contract Development and Manufacturing Organisations (CDMOs), is delighted to welcome Steve Bagshaw to its board as a Non-Executive Director. Steve has almost two decades of board level experience, including leadership roles within Japanese, American and UK Private Equity corporate cultures. His proven acumen drove the rapid growth of a CDMO from $50m to over $600m turnover including transformational acquisitions both in Europe and the US.
Steve’s appointment continues Arcinova’s strategy of strengthening the company board following the appointment of Roger Kilburn as CEO in 2019. Steve’s contribution will be pivotal to the continued growth of the business over the next few years, underpinned by the company’s investor, Business Growth Fund (BGF), who are fully supportive of o ...
The AMR Action Fund totals approx. $1B USD and has been generated by 23 pharma companies in partnership with the WHO. This fund will focus on treatments for drug resistant infections, a major threat to global health and already responsible for 700,000 deaths per year.
Lloyd Payne PhD, Evotec' s EVP Head of Anti-Infectives Operations, discusses what this funding means for the future of AMR:
https://lnkd.in/dM4EVX5 | email@example.com #researchneverstops #AMR #antimicrobialresistance
The research use only kit can be used as a simple alternative to RT-qPCR for SARS-CoV-2 analysis.
University of Birmingham spinout Revitope Oncology Inc has announced a research collaboration and licence agreement with leading Chinese biopharmaceutical company Junshi Biosciences to develop precision cancer therapies that harness the body’s immune response to kill cancer cells while leaving healthy body tissues untouched.
Revitope will leverage its proprietary protein engineering platform with Junshi’s novel antibody components to develop first-in-class dual antigen targeting cancer therapies. Revitope will receive up to $160 million per molecule in milestones and royalties on net sales of 10%. Junshi has also committed to acquire a 9.99% stake in Revitope for $10 million.
Revitope’s technology, known as the T-cell engager antibody circuit (TEAC), has the potential to significantly improve outcomes for millions of cancer patients.
The technology splits antibodies into two halves which are programmed to recognise different antigens. The two halves ...
In the last few months, almost every business has had to make some huge adjustments to how it operates. However, organisations in the healthcare sector have been thrust into the spotlight. They are not only having to ensure they maintain their critical services to patients and healthcare operators, but also are having to navigate a virus pandemic and look after their employees.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.